Fidelity Investments’s AN2 Therapeutics ANTX Stock Holding History

Fidelity Investments’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$295	Buy	+61	New	+$262	﹤0.01%	5343
2026 Q1	–	Sell	-1,200	Closed	-$1.37K	–	5419
2025 Q4	$1.37K	Buy	1,200 +200	+20%	+$234	﹤0.01%	5066
2025 Q3	$1.27K	Buy	+1,000	New	+$1.14K	﹤0.01%	4993
2024 Q4	–	Sell	-300	Closed	-$321	–	5533
2024 Q3	$321	Buy	+300	New	+$521	﹤0.01%	5008
2024 Q1	–	Sell	-670	Closed	-$13.7K	–	5348
2023 Q4	$13.7K	Hold	670	–	–	﹤0.01%	4126
2023 Q3	$10.8K	Hold	670	–	–	﹤0.01%	4089
2023 Q2	$5.7K	Buy	670 +363	+118%	+$2.61K	﹤0.01%	4324
2023 Q1	$3.03K	Buy	307 +56	+22%	+$623	﹤0.01%	4523
2022 Q4	$2.39K	Buy	251 +235	+1,469%	+$3.15K	﹤0.01%	4464
2022 Q3	$0	Buy	+16	New	+$187	﹤0.01%	4813

Other funds holding ANTX

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Fidelity Investments's ANTX Position: Q2 2026 in Review

Fidelity Investments opened a new position in AN2 Therapeutics (ANTX) in Q2 2026: 61 shares worth $295. The stake represents ﹤0.01% of the portfolio and ranks #5343 among its holdings. This is a return to the name: Fidelity Investments previously reported a position in ANTX as recently as Q4 2025.

Fidelity Investments first reported a position in ANTX in Q3 2022 and has held it in 10 quarters since. The position peaked at $13.7K in Q4 2023. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

Fidelity Investments held 61 shares of AN2 Therapeutics worth $295 as of Q2 2026.
AN2 Therapeutics was a new Fidelity Investments position in Q2 2026.
AN2 Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #5343 holding.
Fidelity Investments first reported a position in AN2 Therapeutics in Q3 2022 and has held it in 10 quarters since.
Fidelity Investments's AN2 Therapeutics position peaked at $13.7K in Q4 2023.
66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.